Index | MSCI ACWI IMI Genomic Innovation Select ESG Screened 100 |
Investment focus | Equity, World, Health Care, Social/Environmental |
Fund size | GBP 3 m |
Total expense ratio | 0.30% p.a. |
Replication | Physical (Full replication) |
Legal structure | ETF |
Strategy risk | Long-only |
Sustainability | Yes |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in GBP) | 16.27% |
Inception/ Listing Date | 12 July 2022 |
Distribution policy | Accumulating |
Distribution frequency | - |
Fund domicile | Ireland |
Fund Provider | Xtrackers |
Fund Structure | Company With Variable Capital (SICAV) |
UCITS compliance | Yes |
Administrator | State Street Custodial Services (Ireland) Limited |
Investment Advisor | DWS Investments UK Limited |
Custodian Bank | State Street Custodial Services (Ireland) Limited, Dublin 2 |
Revision Company | Pricewaterhouse Coopers |
Fiscal Year End | 31 December |
Swiss representative | DWS CH AG |
Swiss paying agent | Deutsche Bank (Suisse) SA |
Germany | 30% tax rebate |
Switzerland | ESTV Reporting |
Austria | Tax Reporting Fund |
UK | UK Reporting |
Indextype | - |
Swap counterparty | - |
Collateral manager | |
Securities lending | Yes |
Securities lending counterparty |
Illumina, Inc. | 5.22% |
Bristol Myers Squibb Co. | 5.09% |
Abbott Laboratories | 4.89% |
Vertex Pharmaceuticals, Inc. | 4.61% |
Lonza Group AG | 4.50% |
Agilent Technologies | 4.46% |
Roche Holding AG | 4.30% |
Thermo Fisher Scientific, Inc. | 4.25% |
Danaher Corp. | 4.22% |
Alnylam Pharmaceuticals | 3.83% |
United States | 76.59% |
Switzerland | 9.88% |
Ireland | 3.33% |
China | 3.07% |
Other | 7.13% |
Health Care | 94.90% |
Other | 5.10% |
YTD | +4.24% |
1 month | +2.70% |
3 months | -0.49% |
6 months | +6.20% |
1 year | +11.82% |
3 years | - |
5 years | - |
Since inception (MAX) | -11.98% |
2023 | -8.94% |
2022 | - |
2021 | - |
2020 | - |
Volatility 1 year | 16.27% |
Volatility 3 years | - |
Volatility 5 years | - |
Return per risk 1 year | 0.72 |
Return per risk 3 years | - |
Return per risk 5 years | - |
Maximum drawdown 1 year | -9.86% |
Maximum drawdown 3 years | - |
Maximum drawdown 5 years | - |
Maximum drawdown since inception | -30.08% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
gettex | EUR | XGEN | - - | - - | - |
Borsa Italiana | EUR | XGEN | XGEN IM XGENEUIV | XGEN.MI XGENEURINAV=SOLA | |
London Stock Exchange | USD | XGEN | XGEN LN XGENUSIV | XGEN.L XGENUSDINAV=SOLA | |
London Stock Exchange | GBP | XGES | XGES LN XGENCHIV | XGES.L XGENCHFINAV=SOLA | |
SIX Swiss Exchange | CHF | XGEN | XGEN SW XGENGBIV | XGEN.S XGENGBPINAV=SOLA | |
XETRA | EUR | XGEN | XGEN GR | XGEN.DE |
Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
---|---|---|---|---|
iShares Healthcare Innovation UCITS ETF | 1,035 | 0.40% p.a. | Accumulating | Sampling |
VanEck Genomics and Healthcare Innovators UCITS ETF A | 5 | 0.35% p.a. | Accumulating | Full replication |